Oregon Psilocybin Measure Has Enough Signatures for November Ballot

Kyle Jaeger, writing for Marijuana Moment:

Oregon activists behind an initiative to legalize psilocybin mushrooms for therapeutic purposes announced on Monday that they have secured more than enough valid signatures to qualify for the November ballot.

While the secretary of state’s office hasn’t yet verified all of the signatures, the Yes On IP34 campaign said it has independently determined that they’ve gathered enough to make the cut ahead of a July 2 submission deadline.

The state still needs to verify the most recent batch of signatures, but considering that the initial petition submissions had greater than an 80% approval rate, it’s looking very likely that voters in Oregon will be voting on this measure in November.

---

Post Permalink

Announcing PsyIndex: The World's First Psychedelic Stock Index

From a press release that came out earlier this week at Stockhouse:

CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced the launch of PsyIndex.com, a free premier stock index site and research tool designed for investors, bankers, analysts, journalists and other market participants interested in following and profiting from the emerging multi-billion dollar psychedelics and mushroom industry. The PsyIndex aggregates and tracks the public markets performance of the industry together with associated private companies, breaking news, media coverage and events.

The psychedelics industry could capture a meaningful part of the $28.6 billion global antidepressant market over the coming years as research programs and clinical trials progress towards commercialized treatment solutions. Ketamine, Psilocybin, MDMA and other psychedelics could also play a leading role in treating other high profile medical conditions, including anxiety, post-traumatic stress disorder (PTSD), ADHD and addiction. Newly formed private and public companies focused on the drug development, patient interaction and ancillary segments of the industry have peaked investor interest.

---

Post Permalink

The Effort to Decriminalize Psychedelic Plants in Canada

Wesley Thoricatha, writing for Psychedelic Times:

After the groundbreaking success of Denver’s psilocybin measure and subsequent success of Decriminalize Nature Oakland, a national and now international movement has been sparked to reform harmful drug laws and make psychedelic plants more accessible. In Canada, a new ePetition (e-2534) is gaining traction to decriminalize psychoactive plants, backed by the group Decriminalize Nature Canada.

I’ve impressed time and time again by the series of successful drug policy reforms happening in Canada over the past several years. Now there’s a Decriminalize Nature Canada campaign aiming to decriminalize psychedelic plants at the national level. This interview explains the intention behind the movement and outlines ways that supporters can help.

---

Post Permalink

Study Finds Impressive Long-Term Benefits of MDMA for Treating PTSD

Rich Haridy, writing for New Atlas:

A new study published in the journal Psychopharmacology is presenting a comprehensive look at the long-term efficacy of MDMA-assisted psychotherapy for the treatment of post-traumatic stress disorder (PTSD). The study finds not only do the substantial beneficial effects of the therapy hold strong for well over a year after completing the treatment, but patients continue to improve as time passes following the few MDMA sessions. […]

While several studies have been published outlining positive Phase 2 trial results, this new paper investigates long-term outcomes from the treatment, compiling follow-up data from six prior trials. Around 100 subjects were included in the study.

At the original end-point of the trials, 56 percent of the cohort no longer met the clinical criteria for PTSD. The long-term follow-up data revealed continued improvements in most subjects for well over a year, with 67 percent of the cohort subsequently no longer meeting the PTSD criteria. Other long-term results noted in the cohort include reductions in suicidal thoughts and clinically significant symptom improvements.

Legally treating PTSD with MDMA-assisted psychotherapy is looking more likely than ever.

---

Post Permalink

Dog Rushed to Vet After It Eats Human Poo Filled With Magic Mushrooms at Beach

Emma Parker, writing for Daily Star:

A dog owner was forced to rush her pet Pug to the vet after it ate human faeces containing magic mushrooms while on a walk at the beach.

Don’t eat mushrooms and shit on the beach, y’all.

UPDATE: I’ve had a few people reach out to me to ask if this story is legit. To clear things up, while there’s no way to know whether this news is actually true, personally I seriously doubt that this dog ate human feces containing mushrooms and experienced psychoactive effects. I just found the headline and premise to be hilarious and wanted to share.

---

Post Permalink